Bristol Myers Squibb (NYSE: BMY) recently received a number of ratings updates from brokerages and research firms:
- 10/19/2026 – Bristol Myers Squibb had its “sector perform” rating reaffirmed by Royal Bank Of Canada.
- 10/16/2026 – Bristol Myers Squibb was upgraded by The Goldman Sachs Group, Inc. from “hold” to “strong-buy”.
- 10/13/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by Sanford C. Bernstein.
- 10/13/2026 – Bristol Myers Squibb had its price target lowered by Wells Fargo & Company from $65.00 to $60.00. They now have an “equal weight” rating on the stock.
- 10/12/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $76.00 price target on the stock.
- 10/12/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by William Blair.
- 10/9/2026 – Bristol Myers Squibb had its price target lowered by Bank of America Corporation from $71.00 to $66.00.
- 10/8/2026 – Bristol Myers Squibb had its price target raised by Rothschild & Co Redburn from $51.00 to $53.00. They now have a “neutral” rating on the stock.
- 10/8/2026 – Bristol Myers Squibb had its price target lowered by Cantor Fitzgerald from $59.00 to $53.00. They now have a “neutral” rating on the stock.
- 10/7/2026 – Bristol Myers Squibb had its “underweight” rating reaffirmed by Morgan Stanley. They now have a $41.00 price target on the stock, up from $40.00.
- 10/5/2026 – Bristol Myers Squibb was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $59.00 price target on the stock, down from $73.00.
- 9/23/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $63.00 price target on the stock, up from $61.00.
- 9/23/2026 – Bristol Myers Squibb was upgraded by Zacks Research from “hold” to “strong-buy”.
- 9/16/2026 – Bristol Myers Squibb had its “overweight” rating reaffirmed by Piper Sandler. They now have a $82.00 price target on the stock, up from $75.00.
- 9/10/2026 – Bristol Myers Squibb had its “hold” rating reaffirmed by HSBC Holdings plc. They now have a $65.00 price target on the stock, up from $60.00.
Bristol Myers Squibb Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.
Insider Buying and Selling
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is owned by company insiders.
Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.
The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.
Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.
Further Reading
- Five stocks we like better than Bristol Myers Squibb
- Amprius Technologies’ Next Big Rally Could Be Taking Shape
- 4 Stocks With Demand So Sticky That the AI Sell-Off Barely Touched Them at All
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
Receive News & Ratings for Bristol Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.
